ESR1 and essential thrombocythemia: Although ER IHC-staining was conceived as a predictive biomarker for ET benefit, the relationship between ER nuclear expression and specific immune-suppressive features typical of ER-positive tumors (55), which may dampen responses to ICIs (21), appears to be nonlinear.